Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SkyePharma, a developer of new formulations of known molecules to provide a clinical advantage and life-cycle extension, has concluded initial 'Proof of Concept' study evaluating SKP-1052 for diabetes treatment.
Subscribe to our email newsletter
Currently, the company is in quest of a partner who can fund further development and marketing of the product.
Centre for Endocrinology and Diabetes Sciences clinical professor David Owens said the preliminary study of SKP-1052 has provided encouraging results for a product which would address an unmet medical need in the management of persons with insulin-treated diabetes.
SkyePharma CEO Axel Muller said they look forward to finding a strong development and marketing partner capable of working with them to develop the product for the worldwide diabetes care market.